Liquidia/$LQDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
- Ticker
- $LQDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 216
- Headquarters
- Morrisville, United States
- Website
- www.liquidia.com
Liquidia Metrics
BasicAdvanced
$6B
45.25
$1.48
0.57
-
Price and volume
Market cap
$6B
Beta
0.57
52-week high
$93.61
52-week low
$21.15
Average daily volume
1.5M
Financial strength
Current ratio
2.312
Quick ratio
2.075
Long term debt to equity
0.656
Total debt to equity
0.937
Interest coverage (TTM)
6.33%
Profitability
EBITDA (TTM)
169.768
Gross margin (TTM)
92.54%
Net profit margin (TTM)
30.74%
Operating margin (TTM)
37.39%
Effective tax rate (TTM)
7.29%
Revenue per employee (TTM)
$2,090,000
Management effectiveness
Return on assets (TTM)
27.04%
Return on equity (TTM)
131.82%
Valuation
Price to earnings (TTM)
45.253
Price to revenue (TTM)
12.992
Price to book
30.54
Price to tangible book (TTM)
31.64
Price to free cash flow (TTM)
39.665
Free cash flow yield (TTM)
2.52%
Free cash flow per share (TTM)
1.686
Growth
Revenue change (TTM)
2,233.65%
Earnings per share change (TTM)
-182.32%
3-year revenue growth (CAGR)
193.67%
3-year earnings per share growth (CAGR)
23.37%
What the Analysts think about Liquidia
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Analyst projections of the future price of Liquidia stock.
Bulls say / Bears say
YUTREPIA sales reached approximately $170.4 million in the second quarter of 2026, up 31% sequentially, supporting $74.7 million of net income and $96.3 million of adjusted EBITDA. (Liquidia)
Commercial adoption continues to broaden, with approximately 5,900 unique prescriptions, more than 5,000 patients treated, and over 1,100 prescribers by July 31, 2026; the prescription-to-start conversion rate remained above 85%. (Liquidia)
Liquidia is expanding its growth runway beyond the current YUTREPIA label: the company began enrollment in the pivotal Re-Spire study for L606 and received FDA Fast Track designation for YUTREPIA in systemic-sclerosis-associated Raynaud’s phenomenon, an indication with no currently approved U.S. therapy. (Liquidia)
YUTREPIA remains exposed to material litigation risk: United Therapeutics could still seek an injunction, damages, or restrictions on one or more indications if it prevails in the ongoing patent and trade-secret cases. (SEC filing)
Liquidia remains heavily dependent on YUTREPIA while relying on single-source suppliers for key materials, devices, encapsulation, and packaging; it also had approximately $69.1 million of non-cancelable manufacturing and supply commitments as of June 30, 2026. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Liquidia Financial Performance
Revenues and expenses
Liquidia Earnings Performance
Company profitability
Upcoming events
No upcoming events
Liquidia News
AllArticlesVideos
Funds containing Liquidia
AllUSDGBPEUR
Fund name | Fund size | $LQDA weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.28% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.28% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.16% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.08% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.